The strong revenue beat and sequential growth confirm ANKTIVA's commercial momentum. The fully enrolled pivotal trial de-risks a key regulatory milestone. Traders should monitor the upcoming 10-Q for final numbers and any updates on the BLA submission timeline.
Price Chart
Executive Summary
ImmunityBio reported preliminary Q1 2026 net product revenue of $44.2 million, a 168% year-over-year increase, driven by continued adoption of ANKTIVA. The company also announced full enrollment in its pivotal BCG-naïve NMIBC trial, with a supplemental BLA submission on track for 2026.
Key Financial Metrics
Key Facts
- Preliminary Q1 2026 net product revenue: $44.2 million (168% YoY increase)
- Q1 2026 revenue represents a 15% sequential increase over Q4 2025 ($38.3M)
- Full-year 2025 net product revenue was $113 million, a 700% increase over 2024
- Pivotal BCG-naïve NMIBC CIS trial (QUILT-2.005) is fully enrolled with IDMC confirming adequate statistical power
- Supplemental BLA submission for BCG-naïve NMIBC is on track for 2026
- Cash, cash equivalents, and marketable securities estimated at $380.9 million as of March 31, 2026
Financial Impact
Preliminary Q1 revenue of $44.2M beats consensus of $43.2M and represents a 168% YoY increase
Risk Factors
- Preliminary financials are subject to final adjustments in the upcoming 10-Q
- The company continues to report a net loss, though it narrowed in 2025
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001326110-26-000036 |
| Document: ibrx-2026498xkexhibit991.htm | 0001326110-26-000036 |
| Document: 0001326110-26-000036-index-headers.html | 0001326110-26-000036 |
| Document: 0001326110-26-000036-index.html | 0001326110-26-000036 |
| Document: 0001326110-26-000036.txt | 0001326110-26-000036 |
| 8-K Data (Synthetic) | 0001326110-26-000036 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 8w ago | 8-K | $6.95 $7.87 | ▲ +13.24% | ▲ +14.48% | $10.28 (+47.99%) |
Jul 6, 2026 12w ago | Insider Cluster | $8.91 $7.17 | ▼ −19.53% | ▼ −18.96% | $10.28 (+15.43%) |
Jul 1, 2026 13w ago | Insider Cluster | $9.20 $6.83 | ▼ −25.76% | ▼ −23.58% | $10.28 (+11.79%) |
May 18, 2026 19w ago | 8-K | $7.76 $6.99 | ▼ −9.92% | ▼ −10.91% | $10.28 (+32.54%) |
Apr 9, 2026 25w ago | 8-K | $7.48 $8.38 | ▲ +12.03% | ▲ +4.46% | $10.28 (+37.50%) |
Apr 6, 2026 25w ago | 8-K | $7.08 $7.43 | ▲ +4.94% | ▼ −4.04% | $10.28 (+45.27%) |
Feb 28, 2026 30w ago | Institutional Cluster | $10.44 $6.66 | ▼ −36.21% | ▼ −28.27% | $10.28 (−1.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access